{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"451"}]}],"title":"25 mg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"176"}]}],"title":"50 mg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39"}]}],"title":"75 mg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"100 mg"}],"denoms":[{"counts":[{"groupId":"OG000","value":"680"}],"units":"Participants"}],"description":"In the OL Phase, participants initially received the lowest dose of eltrombopag (25 mg QD) for 2 weeks. If after this time the platelet count was \\<90 Gi/L, participants underwent sequential dose escalation to the next highest dose (50 mg QD for up to 2 weeks), with further dose escalations to 75 mg QD (up to 2 weeks) and 100 mg QD (up to a maximum of 3 weeks) if platelet counts remained \\<90 Gi/L. Participants who achieved platelet count \\>=90 Gi/L on any of the eltrombopag doses in the OL Phase initiated antiviral therapy in the DB Phase.","groups":[{"description":"Participants with a platelet count of \\<75 giga (10\\^9) cells per liter (Gi/L) initially received eltrombopag 25 milligrams (mg) once daily (QD) for 2 weeks. After 2 weeks, if the platelet count was \\<90 Gi/L, participants underwent dose escalation to 50 mg QD for 2 weeks. If platelet counts still remained \\<90 Gi/L, further dose escalations to 75 mg QD (up to 2 weeks) and 100 mg QD (up to a maximum of 3 weeks) were allowed. Participants who achieved platelet counts \\>=90 Gi/L during the OL Phase (maximum of up to 9 weeks) were eligible to enter the Double-blind (DB) Antiviral Treatment Phase, whereas those who failed to reach platelet counts \\>=90 Gi/L were discontinued from eltrombopag and had to attend the post-treatment follow-up visits.","id":"OG000","title":"Eltrombopag: OL Phase"}],"paramType":"NUMBER","populationDescription":"Safety Population. Participants with a platelet count \\>=90 Gi/L and who initiated antiviral therapy during the DB Phase were analyzed.","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 9 in the OL Phase","title":"Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase","type":"SECONDARY","unitOfMeasure":"participants"}